I spoke with Elaine Chen about the results of #HELIOS-B statnews.com/2024/06/24/aln… Certainly I was not expecting these results. A pleasant surprise. Need to dive into the data to understand the meaning of what was reported. Some of the reported data include parts of the OLE

Andreas & Thomas Struengmann Award Honors HAYA Therapeutics Co-founders as Inaugural Winners dlvr.it/T90F2R

HAYA Therapeutics Co-Founders Win Inaugural Andreas & Thomas Struengmann Award dlvr.it/T90FV3

HAYA co-founders, CEO Samir Ounzain (Samir Ounzain) and CTO Daniel Blessing, were honored with the inaugural Andreas & Thomas Struengmann Award on Friday night. The award recognizes DACH-region life science entrepreneurs developing revolutionary technologies. hayatx.com/news-and-publi…

Proud of our #startupfit alumni! ✨✨✨ Inaugural European entrepreneur award crowns HAYA Therapeutics Founders bit.ly/3Ld89Ot via @startuptickerch #Swisstech #VDtech HAYA Therapeutics

Excited to soon embark on a year-long sabbatical in Lausanne 🇨🇭as a visiting prof in Trono Lab EPFL! It’s only an “au revoir”, lab 💕👋

This month began with #WorldRNADay, but at #HAYA, every day is RNA day! 🌍🧬 RNA isn't just a messenger from our DNA—it's a key player in evolution, cell biology, and a game-changer in therapeutics. 🚀 Learn more: nature.com/articles/d4158…

🚀 We are thrilled to announce a multi-year #collaboration with Eli Lilly and Company to discover novel #RegulatoryGenome targets for #Obesity & related #MetabolicConditions. Learn more: hayatx.com/news-and-publi…

𝐏𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩 𝐍𝐞𝐰𝐬: The Co-Founder and CEO of HAYA Therapeutics describes the "dark genome" approach that led to a deal today with Eli Lilly for obesity and metabolic disease. Full video: biotechtv.com//post/haya-the…

Breaking news! HAYA Therapeutics wins Major Collaboration with Lilly 🚀🧬🇨🇭🌐 HAYA Therapeutics, a Swiss biotechnology startup pioneering precision RNA-guided regulatory genome targeting therapeutics for chronic diseases, today announced a multi-year agreement with Eli Lilly and

4September: How does Eli Lilly and Company plan to apply HAYA Therapeutics's long noncoding RNA platform to make new drugs to treat #obesity and metabolic disorders? Read what HAYA CEO Samir Ounzain, PhD told me in my latest for Genetic Engineering & Biotechnology News: genengnews.com/topics/drug-di…

Under a multi-year agreement announced Wednesday, Eli Lilly and Company will leverage Haya Therapeutics’ proprietary RNA-guided genome platform to identify drug targets to address the chronic conditions. #pharma #biospace hubs.li/Q02NCywl0

👇🤯For everybody interested in #lncRNAs, the latest GencodeGenes capture effort and resulting improved annotations are big news! Major increases in overall counts in human and mouse, better overlap with other collections and far higher human-mouse orthology rates

This week, our podcast guest is Samir Ounzain, CEO of Haya Therapeutics. Ounzain was one of the first researchers to publish on lncRNA, also known as the ‘dark genome.’ labiotech.eu/podcast/target…

📣 Today, we are thrilled to welcome Rich Law as #HAYATherapeutics’ #CBO! Looking forward to the future ahead of us. Stay tuned for more exciting news! lnkd.in/eMVFw_8E Welcome to the team Richard!🎉

I’m really thrilled to join up with Samir and the team at HAYA Therapeutics as their new Chief Business Officer!

Thrilled to welcome Rich as our new Chief Business Officer! Rich has a stellar track record in biopharma partnerships, strategic growth, and innovation and his expertise at the intersection of biology and technology has helped reshape drug discovery!

🚀 We're thrilled to announce that #HAYATherapeutics have successfully raised $65Million in #SeriesA round of financing 🎉 A huge #THANKYOU to our TEAM, PARTNERS, and INVESTORS! 🙌 ➡️hayatx.com/news Sofinnova Partners Earlybird VC

Super excited that we get to take this next step in the future of Haya Therapeutics! 🧬 🚀

Brilliant podcast with Samir Ounzain as he shares his journey & what led to the founding of HAYA Therapeutics; a biotech trailblazing an entirely new approach to treating common & chronic diseases by cell reprogramming via the regulatory genome. 🧬❤️🫁podbean.com/media/share/pb…